You are correct. MRC outlines this procedure clearly in his recent post, if people bothered to read it. He even provides a pretty reasonable timeline of how things will play out based on the FDA's procedures and previous AdComs. I understand why people don't like him, but facts should not be so easily dismissed based on the person that provides it.
Amarin has not come forward and said they asked for an amendment to the sNDA...So we don't know...I would think Amarin would provide that information to shareholders as a disclosure issue...
Amarin has been under scrutiny from shareholder discretionary lawfirms. If Amarin did ask for an amendment to the sNDA then we should have been told...
News 
Market Data 
Discover 
